What is the half-life of KPV?

KPV has an approximate elimination half-life of 1 h. Very short-acting — protocols dose 1–2× a day.

How long does KPV stay in your system?

Roughly 97% of a dose has cleared after five half-lives — about ~5 h for KPV. That is the window that matters for washouts, bloodwork and surgery.

KPV is typically administered by the subcutaneous route. Research range: 0.5–1 mg subcutaneous (or oral) daily.

What are the risks of KPV?

Human evidence is early and limited Not FDA-approved Discuss with a clinician if you have an autoimmune condition FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.

KPV

Anti-inflammatory tripeptide. Logging framework across gut, skin, and inflammatory endpoints.

Half-life: 1 h
Out of system: ~5 h
Route: Subcutaneous
Level: Beginner

Very short-acting — protocols dose 1–2× a day. After the last dose, roughly 97% has cleared in ~5 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.

What KPV is used for

Anti-inflammatory tripeptide (fragment of alpha-MSH)
Studied for gut (IBD-context), skin, and inflammatory endpoints
Can be taken oral, subq, or topical

How it's typically used

Research range: 0.5–1 mg subcutaneous (or oral) daily.

What to watch for

Human evidence is early and limited
Not FDA-approved
Discuss with a clinician if you have an autoimmune condition
FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.

Common questions

What is the half-life of KPV?: KPV has an approximate elimination half-life of 1 h. Very short-acting — protocols dose 1–2× a day.
How long does KPV stay in your system?: Roughly 97% of a dose has cleared after five half-lives — about ~5 h for KPV. That is the window that matters for washouts, bloodwork and surgery.
How is KPV taken?: KPV is typically administered by the subcutaneous route. Research range: 0.5–1 mg subcutaneous (or oral) daily.
What are the risks of KPV?: Human evidence is early and limited Not FDA-approved Discuss with a clinician if you have an autoimmune condition FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.

About Healing & recovery

What they are: Repair peptides — short amino-acid chains studied for soft-tissue, tendon, and gut-lining healing. Almost all the evidence is animal or preclinical; human trials are scarce.
How they're run: Reconstituted from a lyophilised (freeze-dried) powder and injected subcutaneously, usually daily, in blocks of 4–6 weeks around a specific injury.
What to watch: None are approved drugs, so purity depends entirely on the source. Effects are gradual — judge a block by whether the injury measurably improved, not by how you feel on day 3.

Full guide

KPV: A Tracking Guide for the Anti-Inflammatory Tripeptide

How to log KPV use across gut, skin, and inflammatory endpoints without overclaiming.

Other healing & recovery

Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.